Publication

Article

Cardiology Review® Online

August 2005
Volume22
Issue 8

Treatment of an 83-year-old man with congestive heart failure

An 83-year-old man with a history of hypertension and atypical chest pain on exertion was admitted to the hospital because of dyspnea. On clinical examination he had minor ankle edema and moderate pulmonary congestion. Cardiac auscultation revealed a discrete systolic murmur. The electrocardiogram showed a sinus rhythm and left ventricular (LV) hypertrophy with strain. An echocardiogram showed LV dilatation (LV end-diastolic diameter 69 mm); the LV ejection fraction was 15%. Minor mitral valve regurgitation was noted. A coronary angiogram revealed no significant coronary artery stenoses. After stabilization, he was referred to an out-patient, nurse-based heart failure management program, placed on an angiotensin-converting enzyme inhibitor, and started uptitration with a beta blocking agent.

Heart failure education was pro-vided to the patient and his relatives, and exercise rehabilitation was offered but refused. Despite these measures he remained in New York Heart Association functional class III, and consequently spironolactone (Aldactone, Spironal) was added. The patient was discharged from the management program on optimal pharmacologic treatment and referred back to his primary care physician for follow-up.

Spironolactone was stopped after 2 months due to serious hyperkalemia. The patient was reevaluated by a cardiologist. The echocardiogram showed an ejection fraction of 10% to 15% and moderate mitral valve regurgitation. The patient was still in sinus rhythm and QRS duration was less than 120 ms. It was concluded that drug therapy could probably not be further optimized and he was not a candidate for cardiac resynchronization therapy. He was not likely to benefit from mitral valve surgery, as regurgitation was only moderate. He was offered referral back to the nurse-led management program for another attempt at instituting spironolactone, but the patient was reluctant to travel to the clinic on a regular basis again. Because his expected life span was short (likely less than 1 year), the patient was supported in his decision to decline further aggressive interventions, and instead plans involving his family and primary care physician were made for home care and support. There comes a point at which palliation should be the objective of medical care.

Related Videos
Orly Vardeny, PharmD: Finerenone for Heart Failure with EF >40% in FINEARTS-HF | Image Credit: JACC Journals
Erin Michos, MD: HFpEF in Women and Sex-Specific Therapeutic Approaches | Image Credit: Johns Hopkins
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Orly Vardeny, PharmD | Credit: JACC Journals
Barry A. Borlaug, MD: Impact of Tirzepatide on Cardiorenal End-Organ Damage | Image Credit: Mayo Clinicn HFpEF
© 2024 MJH Life Sciences

All rights reserved.